AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

So, on February 7, 2025, the FDA approved Emblaveo in combination with metronidazole ... Dear Seeking Alpha readers, let's continue to delve into AbbVie's latest achievements and failures with ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...

AbbVie is navigating significant shareholder ... This collaborative approach, alongside the FDA approval of innovative products like EMBLAVEO, has reinforced investor confidence.

Michael’s elevation came days after AbbVie received FDA approval for their treatment Emblaveo, which targets intra-abdominal infections. As for Gonzalez, he will officially leave the board of ...

AbbVie (ABBV) announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, effective July 1. He will succeed Richard Gonzalez ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...